Evotec Partners with Variant Bio to Innovate Fibrosis Treatments Discovery

• Evotec SE and Variant Bio have entered a strategic partnership to discover and develop treatments for fibrosis.
• The partnership will leverage Variant Bio’s genomic discovery capabilities and VB-Inference platform, as well as Evotec’s expertise in antifibrotic drug discovery.
• The aim is to identify best-in-class small molecules targeting a key fibrotic pathway and progress the programme towards the selection of a clinical development candidate(s).
• The collaboration also includes an opportunity to evaluate unrelated nephrology targets based on human multi-omics data with Evotec’s molecular patient database (“E.MPD”).
• Under the terms of the risk-sharing partnership, Evotec will receive undisclosed research funding and may receive pre-clinical and clinical milestones and/or royalties dependent on the success of the programme.
• Fibrosis is characterised by a marked and pathogenic build-up of the tissue matrix, leading to tissue degeneration in organs, including the liver and lungs, and there is currently no curative treatment for these conditions.

The next important date, Business report 2023 and webcast, at Evotec is on 24.04.2024.

The price of Evotec at the time of the news was 13,325EUR and was up +0,76 % compared with the previous day.
12 minutes after the article was published, the price was 13,330EUR this corresponds to a plus of +0,04 % since publication.
At this time, the index MDAX was at 26.054,09PKT (+0,49 %).

Evotec

+0,15 %

-29,80 %

-34,45 %

-32,86 %

-42,27 %

-71,24 %

-56,31 %

+171,57 %

+289,36 %

ISIN:DE0005664809WKN:566480

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max